查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1479834

全球器官移植市场－2024年至2029年预测

Global Organ Transplant Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 120 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

器官移植市场预计将从2022年的236.86亿美元增加至2029年的439.62亿美元，复合年增长率为9.24%。

由于各种因素，器官移植市场正在经历蓬勃发展。手术、器官保存技术、免疫抑制剂和异种移植等新领域的进步正在不断扩大潜在接受者的范围，提高成功率，提供信心并推动需求。

世界各地糖尿病、高血压和心臟疾病等慢性疾病的增加增加了器官衰竭的可能性和移植的需要。医疗技术的不断进步正在不断改进手术技术和免疫抑制治疗，使器官移植对于更广泛的患者群体更加可行。

此外，老年人口的不断增长和社会对器官捐赠重要性的认识不断提高，个人死后捐赠器官的意愿也在增加。世界各地的许多政府正在主导旨在提高器官捐赠率和改善移植服务可近性的倡议。

市场驱动因素：

  • 急性疾病患者的增加正在推动市场

器官移植市场预计将高速成长。该行业预计将受到环境、技术和政府法规变化的影响，这也将对市场成长构成挑战。此外，技术进步和市场发展也不断增加，包括产品发布、联盟、协议、收购和其他相关因素。

由于创新组织移植服务和治疗器官衰竭的器官移植的需求不断增长。许多疾病通常会导致器官衰竭，包括严重外伤、失血、中毒、药物滥用、白血病、败血症和其他急性疾病。

此外，公众意识提升宣传活动和倡议在教育公众器官捐赠的重要性方面发挥着重要作用。这项宣导活动有可能增加器官的可用性并缩小供需之间的差距。

肾衰竭、肝硬化、心臟衰竭、肺病和糖尿病等慢性疾病的盛行率不断上升，与器官移植需求的增加有直接关係。

此外，根据世界卫生组织（WHO）的数据，非传染性疾病（NCD）对全球死亡率造成重大影响。位居榜首的是心血管疾病，每年夺走 1,790 万人的生命，其次是癌症（930 万人）、慢性呼吸道疾病（410 万人）和糖尿病（其中 200 万人死于糖尿病引起的肾臟疾病）。这些疾病通用共同的危险因素，例如吸烟、缺乏运动、有害饮酒、不健康饮食和空气污染。

此外，美国心臟协会的统计数据显示，目前美国有16.5%的高中生和4.5%的中学生使用烟草製品，引发了烟草使用普及的问题。此外，11.5% 的美国成年人每天或偶尔吸烟。随着这些疾病发病率的增加，对替代器官的需求也增加。

器官移植市场在一个相互作用因素的复杂框架中运作，带来了重大机会，也带来了显着挑战。技术创新、意识努力和道德考量将继续塑造这个充满活力的领域的轨迹，并影响其未来的成长和发展。

  • 老年人口增加

随着世界人口老化，由于老年人慢性病和器官衰竭的盛行率较高，预计对器官移植的需求将激增。根据OECD统计，德国老年人口比例从2020年的21.863%增加到2022年的22.134%。从2015年到2050年，全球60岁及以上老年人的比例预计将增加近一倍，从12%增加到22%。这种人口结构的变化大大扩大了器官捐赠的市场。因为人口老化需要更多的医疗保健服务来维持健康。

  • 领域创新

该地区的创新蓬勃发展，积极关注研究和开发，在器官移植的许多方面取得了突破。外科技术、免疫抑制剂和异种移植等尖端概念的进步证实该地区正在突破医学的界限。

常温灌注是器官保存的开创性技术，代表着向前迈出的一大步。与传统的冷冻保存方法不同，常温灌注采用高温系统，彻底改变了肝臟和心臟移植的方法。

此外，研究人员处于探索革命性途径的最前沿，例如器官製造中的 3D 列印技术。这种利用患者细胞的创新方法有望创造功能性器官，并且可以完全消除对供体器官的依赖。同时，新型免疫抑制剂的开发预示着移植医学的突破。这些药物擅长预防器官排斥，同时减少对患者的副作用，代表着改善移植结果和患者福祉的重要进展。

市场限制因素：

  • 器官捐赠者短缺和手术费用上涨

器官移植市场正面临两大挑战：捐赠器官短缺和移植手术相关的高成本。儘管各方努力提高人们对器官捐赠的认识，但合适器官的供应仍然无法满足不断增长的需求，导致等待移植的人出现巨大缺口。

此外，移植费用，包括移植前评估、手术、术后护理和终身免疫抑制剂，是许多人接受移植的重大障碍。虽然对于预防器官排斥至关重要，但移植后长期使用免疫抑制药物会带来额外的障碍，包括潜在的副作用以及感染疾病和其他健康併发症的风险增加。

器官移植市场依最终用户分为医院、移植中心等。

器官移植市场依最终用户分为医院、移植中心等。医院是主要的治疗中心，大部分的器官移植手术都是在医院进行。另一方面，移植中心是专门从事器官移植的专业医疗机构。

这些中心提供全面的移植服务和专业知识，超越了典型医院所提供的服务。其他包括一部分最终用户，例如门诊手术中心和研究机构。日间手术中心可以承担其服务范围内的某些简单的器官移植手术。

预计北美将占据器官移植市场的很大份额

预计北美将保持器官移植市场的很大一部分，以美国为首。美国以其先进的医疗基础设施而闻名，拥有最先进的医疗设施、熟练的外科医生和高效的器官采购组织。

结果，移植手术的数量显着增加。此外，该地区糖尿病、心臟病等慢性疾病的盛行率不断上升，进一步扩大了需要器官移植的患者数量。

市场发展：

  • 2023 年 9 月 - 加州大学戴维斯分校健康推出新的成人肝臟移植计划，扩大加州大学戴维斯分校移植中心的现有服务，并为肝病患者提供全面的护理。

目录

第一章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球器官移植市场：依产品类型

  • 介绍
  • 器官保存解决方案
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 移植诊断
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 纸巾产品
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章全球器官移植市场：依器官分类

  • 介绍
  • 心
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 肠
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 肾
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 肝
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 肺
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 胰臟
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章全球器官移植市场：依最终用户分类

  • 介绍
  • 医院
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 移植中心
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第八章全球器官移植市场：按地区

  • 介绍
  • 北美洲
    • 依产品类型
    • 依器官类型
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 依产品类型
    • 依器官类型
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 依产品类型
    • 依器官类型
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 依产品类型
    • 依器官类型
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 依产品类型
    • 依器官类型
    • 按最终用户
    • 按国家/地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • OrganOx Limited
  • GlaxoSmithKline Plc.
  • Pfizer
  • XVIVO Perfusion AB（Organ Assist BV）
  • Paragonix Technologies Inc.
  • Novartis AG
  • Preservation Solution Inc.
  • Water Medical System LLC
  • Sanofi SA
  • Bridge to Life Ltd.
简介目录
Product Code: KSI061612957

The global organ transplant market is projected to rise at a compound annual growth rate (CAGR) of 9.24% to reach a market valuation of US$43.962 billion by 2029, from US$23.686 billion in 2022.

The global organ transplant market experiences dynamic growth fueled by a multitude of factors. Progress in surgical procedures, organ preservation techniques, immunosuppressive medications, and the emerging realm of xenotransplantation continually broaden the pool of potential recipients and elevate success rates, instilling confidence and driving demand.

A rising global incidence of chronic ailments such as diabetes, hypertension, and cardiac conditions heightens the likelihood of organ failure, thus magnifying the need for transplantations. Ongoing advancements in medical technology continuously refine surgical methodologies and immunosuppressive treatments, rendering organ transplantation increasingly feasible for a broader patient demographic.

Moreover, the expanding geriatric population and increasing public consciousness regarding the significance of organ donation contribute to a growing willingness among individuals to donate their organs posthumously. Numerous governments worldwide are spearheading initiatives aimed at elevating organ donation rates and enhancing accessibility to transplant services.

Market Drivers:

  • Increasing cases of acute diseases propels the market.

The global organ transplant market is projected to rise at a high growth rate. The industry is expected to be affected by changing environmental, technological, and governmental regulations, which are anticipated to challenge market growth as well. In addition, the increasing technological advancements and market developments, including product launches, collaborations, agreements, acquisitions, and other related factors.

Owing to the growing demand for innovative tissue transplantation services and organ transplantation to treat organ failure. Many conditions, including severe trauma, blood loss, poisoning, drug abuse, leukemia, sepsis, and other acute illnesses, are typically the cause of organ failure.

Further, public awareness campaigns and initiatives play a crucial role in educating the populace about the importance of organ donation. This educational effort holds promise for boosting the availability of organs, potentially bridging the gap between supply and demand.

The rising prevalence of chronic ailments like kidney failure, liver cirrhosis, heart failure, lung diseases, and diabetes directly correlates with the escalating demand for organ transplants.

Moreover, according to the World Health Organization (WHO), non-communicable diseases (NCDs) contribute significantly to global mortality rates. Cardiovascular diseases top the list, claiming 17.9 million lives annually, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million, including deaths due to kidney disease resulting from diabetes). These diseases share common risk factors, including tobacco use, physical inactivity, harmful alcohol consumption, unhealthy diets, and air pollution.

Furthermore, statistics from the American Heart Association underline the concerning prevalence of tobacco use, with 16.5% of US high school students and 4.5% of middle school students reporting current tobacco product use. Additionally, 11.5% of US adults admit to using cigarettes daily or occasionally. As the incidence of these diseases rises, so does the demand for replacement organs.

The global organ transplant market operates within a complex framework of interacting factors, presenting significant opportunities alongside notable challenges. Technological innovations, heightened awareness efforts, and ethical considerations will continue to shape the trajectory of this dynamic field, influencing its future growth and development.

  • Growing Geriatric Population

As the global population ages, the demand for organ transplants is expected to surge due to the higher prevalence of chronic illnesses among older adults, which often result in organ failure. According to OECD statistics, Germany saw its geriatric population rise from 21.863% in 2020 to 22.134% in 2022. Over the period from 2015 to 2050, the proportion of individuals aged over 60 worldwide is projected to nearly double from 12% to 22%. This demographic shift significantly expands the market for organ donation, as the elderly population requires increased healthcare services to maintain their well-being.

  • Innovation in the field

Innovation is thriving in the region, with a robust focus on research and development yielding breakthroughs in various aspects of organ transplantation. Advancements in surgical techniques, immunosuppressive medications, and cutting-edge concepts like xenotransplantation underscore the region's commitment to pushing the boundaries of medical science.

Normothermic perfusion, a pioneering technology in organ preservation, represents a significant stride forward. Unlike traditional cold storage methods, normothermic perfusion employs a warm system, revolutionizing the approach to liver and cardiac transplants, albeit yet to be utilized for kidney transplants.

Furthermore, researchers are at the forefront of exploring revolutionary avenues such as 3D printing technology in organ creation. By harnessing a patient's cells, this innovative approach holds promise in fabricating functional organs, potentially obviating the reliance on donor organs altogether, though still in its nascent stages. Concurrently, the development of novel immunosuppressive drugs signals a leap forward in transplant care. These medications are engineered to be more adept at thwarting organ rejection while mitigating adverse effects on patients, representing a significant advancement in enhancing transplant outcomes and patient well-being.

Market Restraint:

  • Shortage of organ donors and high cost of operations

The global organ transplant market grapples with two primary challenges: a shortage of donor organs and the high costs associated with transplantation procedures. Despite concerted efforts to raise awareness about organ donation, the supply of suitable organs falls short of the increasing demand, creating a significant gap for individuals awaiting transplants.

Moreover, the expense of transplantation, encompassing pre-transplant evaluations, surgery, post-operative care, and lifelong immunosuppressive medication, poses a formidable barrier to access for many. While vital for preventing organ rejection, the prolonged use of immunosuppressive drugs post-transplantation presents additional hurdles, with potential adverse side effects and heightened risks of infections and other health complications.

Global organ transplant market segmentation by end-users into hospitals, transplant centers, and others.

The global organ transplant market is segmented by end-users, including hospitals, transplant centers, and other entities. Hospitals serve as the primary treatment hubs where a significant portion of organ transplant procedures take place. Transplant centres, on the other hand, represent specialized healthcare facilities exclusively focused on organ transplantation.

These centers offer a comprehensive array of transplant services and specialized expertise, surpassing what is typically available in general hospitals. Others encompass a smaller subset of end-users, such as ambulatory surgical centers and research institutions. Ambulatory surgical centres may undertake certain types of simpler organ transplant procedures within their scope of services.

North America is anticipated to hold a significant share of the global organ transplant market

North America is expected to maintain a substantial portion of the global organ transplant market, with the United States leading the forefront. Renowned for its sophisticated healthcare infrastructure, the US possesses cutting-edge medical facilities, proficient surgeons, and efficient organ procurement organizations.

Consequently, this leads to a notable increase in the number of transplant procedures conducted. Additionally, the region grapples with a rising prevalence of chronic conditions such as diabetes and heart disease, further expanding the pool of patients necessitating organ transplants.

Market Developments:

  • September 2023- UC Davis Health launched a new adult liver transplant program, expanding the existing services of the UC Davis Transplant Center and providing comprehensive care to patients with liver disease.

Market Segmentation:

By Product Type

  • Organ preservation solutions
  • Transplant diagnostics
  • Tissue products
  • Others

By Organ Type

  • Heart
  • Intestine
  • Kidney
  • Liver
  • Lung
  • Pancreas

By End-Users

  • Hospitals
  • Transplant Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL ORGAN TRANSPLANT MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Organ preservation solutions
    • 5.2.1. Market opportunities and trends
    • 5.2.2. Growth prospects
    • 5.2.3. Geographic lucrativeness
  • 5.3. Transplant diagnostics
    • 5.3.1. Market opportunities and trends
    • 5.3.2. Growth prospects
    • 5.3.3. Geographic lucrativeness
  • 5.4. Tissue products
    • 5.4.1. Market opportunities and trends
    • 5.4.2. Growth prospects
    • 5.4.3. Geographic lucrativeness
  • 5.5. Others
    • 5.5.1. Market opportunities and trends
    • 5.5.2. Growth prospects
    • 5.5.3. Geographic lucrativeness

6. GLOBAL ORGAN TRANSPLANT MARKET BY ORGAN TYPE

  • 6.1. Introduction
  • 6.2. Heart
    • 6.2.1. Market opportunities and trends
    • 6.2.2. Growth prospects
    • 6.2.3. Geographic lucrativeness
  • 6.3. Intestine
    • 6.3.1. Market opportunities and trends
    • 6.3.2. Growth prospects
    • 6.3.3. Geographic lucrativeness
  • 6.4. Kidney
    • 6.4.1. Market opportunities and trends
    • 6.4.2. Growth prospects
    • 6.4.3. Geographic lucrativeness
  • 6.5. Liver
    • 6.5.1. Market opportunities and trends
    • 6.5.2. Growth prospects
    • 6.5.3. Geographic lucrativeness
  • 6.6. Lung
    • 6.6.1. Market opportunities and trends
    • 6.6.2. Growth prospects
    • 6.6.3. Geographic lucrativeness
  • 6.7. Pancreas
    • 6.7.1. Market opportunities and trends
    • 6.7.2. Growth prospects
    • 6.7.3. Geographic lucrativeness

7. GLOBAL ORGAN TRANSPLANT MARKET BY END-USERS

  • 7.1. Introduction
  • 7.2. Hospitals
    • 7.2.1. Market opportunities and trends
    • 7.2.2. Growth prospects
    • 7.2.3. Geographic lucrativeness
  • 7.3. Transplant Centers
    • 7.3.1. Market opportunities and trends
    • 7.3.2. Growth prospects
    • 7.3.3. Geographic lucrativeness
  • 7.4. Others
    • 7.4.1. Market opportunities and trends
    • 7.4.2. Growth prospects
    • 7.4.3. Geographic lucrativeness

8. GLOBAL ORGAN TRANSPLANT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Product Type
    • 8.2.2. By Organ Type
    • 8.2.3. By End-users
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Trends and Opportunities
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Trends and Opportunities
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Trends and Opportunities
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Product Type
    • 8.3.2. By Organ Type
    • 8.3.3. By End-users
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Trends and Opportunities
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Trends and Opportunities
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Trends and Opportunities
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Product Type
    • 8.4.2. By Organ Type
    • 8.4.3. By End-users
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Trends and Opportunities
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Trends and Opportunities
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. UK
        • 8.4.4.3.1. Market Trends and Opportunities
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Italy
        • 8.4.4.4.1. Market Trends and Opportunities
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Trends and Opportunities
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Product Type
    • 8.5.2. By Organ Type
    • 8.5.3. By End-users
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Trends and Opportunities
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. Israel
        • 8.5.4.2.1. Market Trends and Opportunities
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Trends and Opportunities
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Product Type
    • 8.6.2. By Organ Type
    • 8.6.3. By End-users
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Trends and Opportunities
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. Japan
        • 8.6.4.2.1. Market Trends and Opportunities
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Trends and Opportunities
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Trends and Opportunities
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Indonesia
        • 8.6.4.5.1. Market Trends and Opportunities
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Taiwan
        • 8.6.4.6.1. Market Trends and Opportunities
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Thailand
        • 8.6.4.7.1. Market Trends and Opportunities
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Trends and Opportunities
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisition, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. OrganOx Limited
  • 10.2. GlaxoSmithKline Plc.
  • 10.3. Pfizer
  • 10.4. XVIVO Perfusion AB (Organ Assist B.V.)
  • 10.5. Paragonix Technologies Inc.
  • 10.6. Novartis AG
  • 10.7. Preservation Solution Inc.
  • 10.8. Water Medical System LLC
  • 10.9. Sanofi S.A
  • 10.10. Bridge to Life Ltd.